



Performance Enhanced Pharmaceuticals providing fast relief when it's needed most


EquiTech Corporation
TSXV: "EQT"

Corporate Fact Sheet

EquiTech is a specialty pharmaceutical company developing better absorbing versions of existing oral medications. Using our Enhanced Absorption Technology platform we have developed our lead compound, ZAG-1701, which is a faster absorbing ibuprofen caplet for acute pain relief. ZAG-1701 is the first Performance Enhanced Pharmaceutical product from our development pipeline ready to begin Phase II clinical trials

Corporate Highlights

- **Oral medications that work better:** proprietary Enhanced Absorption Technology platform is a sophisticated tool to enhance the absorption of a wide range of oral drugs
- **ZAG-1701 a faster absorbing ibuprofen tablet:**
 - GMP manufacture of clinical trial quantities complete
 - Phase II clinical trial in patients experiencing the pain of wisdom tooth extraction ready to start
- **Lead compound fulfills large market need:** ZAG-1701 targets pain relief. More than half of pain sufferers complain that current medication is not completely effective (*Survey of Pain in America, 1999*); global pain medications market greater than \$US 38B (2002)
- **World-leading science:** our scientists are known for excellence in pharmaceutical reformulation and product development
- **Scientific advisory board:** chaired by recognized global leader in pain relief clinical trials



ZAG-1701 absorbs faster than standard ibuprofen in pain-mimicking animal model

Financial Highlights

Audited, as of Dec 31, 2003 Cdn\$

Current assets:	400,924
Net (loss) for the 12-month period ending Dec 31, 2003	(634,611)
Total number of shares:	6,621,874

Fast Facts (as at June 30, 2004)

Name:	EquiTech Corporation
Symbol:	EQT
Exchange:	TSXV (Venture Exchange)
Head Office:	Edmonton, Alberta, Canada
Shares Outstanding:	approx. 14.2 M
Market Cap:	approx. \$ 2.13 M Cdn

Our Technology and Products

- EQT scientists made ground-breaking discovery that **pain relief products don't work as well when patient is actually in pain.**
- Technology platform to **enhance absorption of drugs** works even when patient is in pain or when stomach activity is reduced.
- **Lead ZAG-1701 ibuprofen product** absorbs faster than standard ibuprofen (see graph)
- **COX-2 inhibitor** enhanced absorbing formulation developed using proprietary pain mimicking animal model.
- **Other pain relief products** in late stage research and development.
- **Proprietary animal model** mimics the reduced stomach activity that occurs in response to acute pain and is also characteristic of the geriatric patient
- **Additional products** based on **Enhanced Absorption Technology** will be developed for other conditions where fast relief is needed or where reduced GI function is a factor.
- U.S. and international **patents pending** on EquiTech's lead compounds and innovative research tools

Key Contact

James Chivers-Wilson
President & Chief Executive Officer
Tel: 780.430.1633 Fax: 780.430.1355
james@equitechcorporation.com

EquiTech Corporation
Suite 3048, 8308 114th Street
Edmonton, Alberta, Canada T6G 2E1
<http://www.equitechcorporation.com>

This document may contain forward-looking statements, i.e. information that is not strictly historical, concerning EquiTech's business and prospects. Forward-looking statements are subject to a number of risks and uncertainties. Actual events and results may differ materially from those discussed in this document, due to factors including research, development, commercial and market risks.